Engineered immune cells primed with decitabine show promise for tough lymphoma
NCT ID NCT04697940
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing a new type of immunotherapy for people with B-cell Non-Hodgkin's lymphoma that has returned or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in the lab to target two proteins (CD19 and CD20) on cancer cells, and are primed with a drug called decitabine before being given back. The study aims to find the safest dose and see how well it works in up to 33 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decitabine-primed tandem CD19/CD20 CAR T cells
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat B-cell Non-Hodgkin's lymphoma that has come back or not responded to standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants (33). The treatment may cause serious side effects like cytokine release syndrome, and it is not yet proven to work better than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China